Relying on its unique hypoglycemic mechanism, it reduces the absorption of glucose in the gastrointestinal tract by inhibiting SGLT-1 and increases the excretion of glucose by the kidneys by inhibiting SGLT-2.[6] Studies have found that SOTA can not only treat T2DM but can also treat T1DM.[7] Currently, SOTA has completed phase iii clinical trials (inTandem1, inTandem2, inTandem3).[8] The purpose of this meta-analysis is to analyze the therapeutic effect and safety of SOTA on T1DM, thereby providing evidence for the treatment of T1DM by SOTA. The gene discussed is SLC5A1; the disease is type 1 diabetes mellitus.